Trial Profile
Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Gemcitabine; Oxaliplatin
- Indications Biliary cancer; Gallbladder cancer
- Focus Therapeutic Use
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2011 New trial record